文献速递冠心病血脂与心血管预防

依洛尤单抗在冠心病严重程度与范围不同患者中的临床获益:FOURIER 分析

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
PubMed 文献 · Circulation · 2018-01-01

FOURIER 试验纳入 22 351 例既往心肌梗死患者,按距最近心梗时间、既往心梗次数及残余多支冠脉病变分组,评估依洛尤单抗的疗效。结果显示,距最近心梗≤2 年、多次心梗或残余多支病变者心血管风险更高,且依洛尤单抗带来的相对与绝对风险降低更显著。

要点

  • 距最近心梗≤2 年、多次心梗或残余多支病变是心血管事件的独立预测因素。
  • 上述高危亚组使用依洛尤单抗后主要终点相对风险降低约 18%–21%,绝对风险降低>3%。
  • 低危亚组相对风险降低仅 5%–8%,绝对风险降低约 1%。

核心结论

  • 距最近心梗时间短、多次心梗或残余多支冠脉病变的患者主要血管事件风险高,接受依洛尤单抗降低 LDL-C 后风险下降更明显。

研究设计与样本

  • FOURIER 试验的事后亚组分析,纳入 22 351 例既往心肌梗死患者,按距最近心梗时间、既往心梗次数及残余多支冠脉病变(≥2 支大血管狭窄≥40%)分组。

主要发现

  • 距最近心梗≤2 年、既往心梗≥2 次、残余多支冠脉病变者分别占 38%、24%、25%。
  • 多变量校正模型显示,距最近心梗时间短、多次心梗、残余多支病变对主要终点的校正 HR 分别为 1.37(95%CI 1.22–1.53)、1.78(95%CI 1.59–1.99)、1.39(95%CI 1.24–1.56),均 P<0.001。
  • 高危亚组主要终点相对风险降低分别为 20%(HR 0.80,95%CI 0.71–0.91)、18%(HR 0.82,95%CI 0.72–0.93)、21%(HR 0.79,95%CI 0.69–0.91);低危亚组分别为 5%(HR 0.95,95%CI 0.85–1.05)、8%(HR 0.92,95%CI 0.84–1.02)、7%(HR 0.93,95%CI 0.85–1.02)。
  • 高危组 3 年绝对风险降低分别为 3.4%、3.7%、3.6%,低危组分别约 0.8%、1.3%、1.2%。

临床怎么用

  • 对近期心梗、多次心梗或残余多支冠脉病变等高危患者,可优先考虑联用依洛尤单抗以强化 LDL-C 降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab significantly reduced major vascular events in patients with stable atherosclerotic cardiovascular disease, including patients with prior myocardial infarction (MI). Within the broad group of patients with prior MI, we hypothesized that readily ascertainable features would identify subsets who derive greater clinical risk reduction with evolocumab. METHODS: The 22 351 patients with a prior MI were characterized on the basis of time from most recent MI, number of prior MIs, and presence of residual multivessel coronary artery disease (≥40% stenosis in ≥2 large vessels). The relative and absolute risk reductions in major vascular events, including the primary end point (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) and the key secondary end point (cardiovascular death, MI, or stroke), with evolocumab in these subgroups were compared. RESULTS: A total of 8402 patients (38%) were within 2 years of their most recent MI; 5285 patients (24%) had ≥2 prior MIs; and 5618 patients (25%) had residual multivessel coronary artery disease. In a multivariable-adjusted model that simultaneously included all 3 high-risk features and other baseline covariates, more recent MI, multiple prior MIs, and residual multivessel coronary disease remained independent predictors of cardiovascular outcomes, with adjusted hazard ratios (HRs) for the primary end point of 1.37 (95% confidence interval [CI],1.22-1.53), 1.78 (95% CI, 1.59-1.99), and 1.39 (95% CI, 1.24-1.56; all P<0.001). The relative risk reductions with evolocumab for the primary end point tended to be greater in the high-risk subgroups and were 20% (HR, 0.80; 95% CI, 0.71-0.91), 18% (HR, 0.82; 95% CI, 0.72-0.93), and 21% (HR, 0.79; 95% CI, 0.69-0.91) for those with more recent MI, multiple prior MIs, and residual multivessel coronary artery disease, whereas they were 5% (HR, 0.95; 95% CI, 0.85-1.05), 8% (HR, 0.92; 95% CI, 0.84-1.02), and 7% (HR, 0.93; 95% CI, 0.85-1.02) in those without, respectively. Given the higher baseline risk, the respective absolute risk reductions at 3 years exceeded 3% in the high-risk groups (3.4%, 3.7%, and 3.6%) versus ≈1% in the low-risk groups (0.8%, 1.3%, and 1.2%). CONCLUSIONS: Patients closer to their most recent MI, with multiple prior MIs, or with residual multivessel coronary artery disease are at high risk for major vascular events and experience substantial risk reductions with low-density lipoprotein cholesterol lowering with evolocumab. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01764633.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. Circulation. 2018. PMID: 29626068. doi:10.1161/CIRCULATIONAHA.118.034309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。